Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial.
Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial.
复制标题
口服 S-腺苷甲硫氨酸治疗抑郁症：一项随机、双盲、安慰剂对照试验。
DOI：
10.1176/ajp.147.5.591
复制
发表时间：
1990
期刊：
影响因子：
--
通讯作者：
Gerner,RH
中科院分区：
文献类型：
--
作者：
Kagan,BL;Sultzer,DL;Rosenlicht,N;Gerner,RH
甲基化与精神疾病的病因有关。肠外注射的 S-腺苷甲硫氨酸是一种甲基供体，已被证明是一种有效的抗抑郁药。作者在一项针对 15 名重度抑郁症住院患者的随机、双盲、安慰剂对照试验中研究了口服 S-腺苷甲硫氨酸的抗抑郁作用。结果表明，口服S-腺苷甲硫氨酸是一种安全、有效的抗抑郁药，副作用少，起效快。 S-腺苷甲硫氨酸在没有躁狂病史的患者中诱发躁狂症。 S-腺苷甲硫氨酸对于不能耐受三环类抗抑郁药的患者可能有用。这些发现支持甲基化在抑郁症病理生理学中的作用。
Methylation has been implicated in the etiology of psychiatric illness. Parenteral S-adenosylmethionine, a methyl group donor, has been shown to be an effective antidepressant. The authors studied the antidepressant effect of oral S-adenosylmethionine in a randomized, double-blind, placebo-controlled trial for 15 inpatients with major depression. The results suggest that oral S-adenosylmethionine is a safe, effective antidepressant with few side effects and a rapid onset of action. S-Adenosylmethionine induced mania in a patient with no history of mania. S-Adenosylmethionine may be useful for patients who cannot tolerate tricyclic anti-depressants. These findings support a role for methylation in the pathophysiology of depression.